No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DAVE240517P50000
- 0.05
- -4.85-98.98%
15min DelayClose May 17 15:59 ET
0.05High0.05Low
0.05Open4.90Pre Close5 Volume13 Open Interest50.00Strike Price25.00Turnover0.00%IV0.24%PremiumMay 17, 2024Expiry Date0.17Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma996.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Dave to Participate in the FT Partners Equity Research Weekly Forum on May 17th
LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (Nasdaq: DAVE), one of the nation's leading neobanks, today announced that the Company will participate in the upcom
FinTech Giant's Profits Soar on Crypto Trading Surge
Robinhood (NASDAQ:HOOD) reported a significant earnings beat for the first quarter, driven by a surge in crypto trading volumes and increased net...
Dave Inc(DAVE.US) 10% Shareholder Sells US$5.38 Million in Common Stock
$Dave Inc(DAVE.US)$ 10% Shareholder Section 32 Fund 1, LP sold 110K shares of common stock on May 10, 2024 at an average price of $48.9 for a total value of $5.38 million. This transaction involves ot
Dave Inc. (NASDAQ:DAVE) Q1 2024 Earnings Call Transcript
Dave Is Maintained at Outperform by Barrington Research
Dave Is Maintained at Outperform by Barrington Research
Express News | Dave Inc : Barrington Research Raises Target Price to $65 From $45
Comments
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings(SWVL.US$718.40%
![]()
$Root Inc(ROOT.US$564.60%
![]()
$Elevation Oncology(ELEV.US$561.08%
![]()
$JanOne(JAN.US$554.05%
![]()
$GeneDx Holdings(WGS.US$520.71%
![]()
$Corbus Pharmaceuticals(CRBP.US$513.25%
![]()
$AGBA Group(AGBA.US$482.90%
![]()
$Janux Therapeutics(JANX.US$431.22%
![]()
$Dave Inc(DAVE.US$4...
A quick recap for the month ending April 30, 2024.
4
1
Despite strong revenue growth, Dave's low P/S ratio may indicate investor belief of underperformance in the broader industry. Shareholders may think recent performance has peaked, leading to lower selling prices. The low P/S ratio could signal price risks if medium-term revenue trends persist, but investors anticipate future revenue volatility.
Dave Inc.'s CEO, Jason Wilk, sees the recent transaction as a major advancement for the company, offering a unique chance to increase shareholder value. He remains confident in the company's ability to meet its growth and profitability goals in the future quarters.
$Dave Inc(DAVE.US$ Something not right… it is now at 9.05
Despite strong revenue growth that outpaces the industry, Dave's P/S ratio is surprisingly low. This could suggest underlying risks to the company's future performance as investors may not be convinced the company can maintain its recent growth rates.
Read more
Mars MoooOP :